{"fetched":"2026-09-17","congress":{"id":"asco","label":"ASCO Annual Meeting","year":2026,"journal":"Journal of Clinical Oncology","window":{"from":"2026-05-10","to":"2026-06-20"},"source":"https://api.crossref.org/"},"total":7364,"considered":7222,"matched":3191,"items":[{"doi":"10.1200/jco.2026.44.16_suppl.4129","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4129","title":"A phase I/II study of CDX-1140, a CD40 agonist, in combination with capecitabine and oxaliplatin (CAPOX) and pembrolizumab in subjects with biliary tract carcinoma: Phase 1 results.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","capecitabine-temozolomide","capecitabine","oxaliplatin","capox"],"trials":["nct05224141","nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct05256290","nct03960840","nct05797168","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07280832","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct06144671","nct07148128","nct06139575","nct05204862","nct04115306","nct06735144","nct06212076","nct07605962","nct07751042","nct06819215","nct05367778","nct07145255","nct06993844","nct06730009","nct05990452","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct07050641","nct07073534","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3016","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3016","title":"A phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: First disclosure of clinical data.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129"],"trials":["nct06265025","nct06622486","nct04140500","nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3155","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3155","title":"A phase 1/2, first-in-human, open-label, dose-escalation and -expansion study of TAK-188, a novel antibody-drug conjugate (ADC) targeting CCR8 + regulatory T cells, in adult patients with locally advanced or metastatic solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06265025","nct06622486","nct04140500","nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2693","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2693","title":"ASCEND: A phase 1/2, dose-escalation, optimization, and dose-expansion study to evaluate the safety and antitumor activity of CR-001 in adults with locally advanced or metastatic solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06265025","nct06622486","nct04140500","nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps7580","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps7580","title":"A phase 1/2 study of mRNA-2808 in participants with relapsed or refractory multiple myeloma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03915184","nct06232096","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05704049","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05947851","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3159","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3159","title":"A phase 1, first-in-human study of DS3610, a stimulator of interferon genes (STING) agonist antibody-drug conjugate (ADC), in patients with advanced/metastatic solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":["adc","sting-agonist"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2680","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2680","title":"A phase 1, first-in-human study of DS5361, a small-molecule, nonsense-mediated mRNA decay (NMD) inhibitor in patients with advanced/metastatic solid tumors (parts 1 and 2).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15162","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15162","title":"A phase 1 study to evaluate safety, tolerability, and pharmacokinetics of LNP8701 (SOS1 inhibitor) in subjects with metastatic solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2685","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2685","title":"A phase 1 study of PHST001, an anti-CD24 monoclonal antibody, in adult patients with advanced relapsed and/or refractory solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03686124","nct05958121","nct03709680","nct06150885","nct05704049","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05947851","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8106","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8106","title":"Safety, pharmacokinetic, and preliminary efficacy of SNC115 in patients with relapsed/refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC): A phase 1 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07365241","nct07744256","nct07480213","nct07325136","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05281471","nct06463665","nct05947851","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2587","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2587","title":"Safety, PK/PD, and efficacy results from Expand-1: A phase 1 dose escalation study of the novel PD-1 targeted IL-2R-βγ agonist sunekafusp alpha (ANV600) as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab"],"trials":["nct05431270","nct05224141","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05281471","nct06463665","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8558","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8558","title":"Safety and efficacy of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced non-small cell lung cancer: Results from a phase 1/2 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ai-081"],"trials":["nct05318573","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05281471","nct06463665","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["ctla4","pd1","vegf"],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7003","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7003","title":"A phase 1 study of the PRMT5 inhibitor AZD3470 in patients with relapsed/refractory classic Hodgkin lymphoma (PRIMAVERA).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["azd3470"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05947851","nct07075328","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126","prima"],"targets":["prmt5-mtap"],"cancers":["hodgkin-lymphoma","non-hodgkin-lymphoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3161","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3161","title":"A phase 1, multicenter, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SBO-154 in subjects with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06922591","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05281471","nct06463665","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1094","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1094","title":"A phase 1/2, first-in-human study of AVZO-021, a selective cyclin-dependent kinase 2 inhibitor (CDK2i), as monotherapy and in combination for patients with advanced solid tumors, including hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) breast cancer (BC) and cyclin E1 (CCNE1)–amplified solid tumors: Updated safety and efficacy results.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["avzo-021"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05281471","nct06463665","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e17043","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e17043","title":"Efficacy and safety of mevrometostat (M) in combination with enzalutamide (E) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from a phase 1 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mevrometostat","enzalutamide"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05281471","nct06463665","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1066","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1066","title":"First disclosure of frontline treatment (1L tx) with the selective CDK4 inhibitor BGB-43395 in combination with letrozole for metastatic HR+/HER2− breast cancer (BC): A phase 1 safety expansion.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["letrozole","bgb-43395"],"trials":["nct04862663","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126","nct06790693"],"targets":["her2","cdk4-6"],"cancers":["breast-cancer"],"technologies":["cdk46-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.8564","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8564","title":"Inhaled delivery of KB707, a novel HSV-based immunotherapy, in combination with pembrolizumab in advanced non–small cell lung cancer: A phase 1/2 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab"],"trials":["nct05318573","nct05224141","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2700","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2700","title":"A phase 1 trial of the oncolytic virus SVV-001 with nivolumab and ipilimumab in patients with high-grade neuroendocrine neoplasms.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["mds"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3165","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3165","title":"A phase 1/2 first-in-human study of TH9619 in patients with advanced refractory solid tumors (ODIN).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03709680","nct06150885","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5508","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5508","title":"A phase 1/2 study of the next-generation nectin-4–targeting antibody-drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["crb-701"],"trials":["nct07051486","nct04906993","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["nectin4"],"cancers":["cervical"],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.8516","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8516","title":"A phase 1/2 study of TSN1611, a highly selective oral KRAS G12D inhibitor, in solid tumors: Efficacy and safety in KRAS G12D–mutated NSCLC patients.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06922591","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05281471","nct06463665","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["kras"],"cancers":[],"technologies":["kras-inhibitors"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5638","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5638","title":"A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab in a low-grade serous ovarian cancer cohort: Trial in progress.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cemiplimab","mcla-129","ubamatamab"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["muc16"],"cancers":["low-grade-serous-ovarian-cancer","ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6040","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6040","title":"Depth and durability of response with TGF-β trapping in recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC): Long-term results from two expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ficerafusp-alfa","pembrolizumab"],"trials":["nct05224141","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5046","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5046","title":"Safety and efficacy of QLC5508 (MHB088C) in heavily-treated patients with metastatic castration-resistant prostate cancer: Updated data from a phase 1/2 trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["qlc5508"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05281471","nct06463665","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6058","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6058","title":"The impact of depth of response on long-term clinical outcomes: Exploratory analyses from multiple expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic (R/M) HPV-negative head and neck carcinoma (HNSCC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ficerafusp-alfa","pembrolizumab"],"trials":["nct05224141","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4626","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4626","title":"Updated efficacy and safety of SHR-1501, an IL-15RαFc superagonist, with or without Bacille Calmette Guerin (BCG) for high-risk non-muscle invasive bladder cancer (NMIBC): A phase 1/2 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["shr-1501"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05281471","nct06463665","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["urothelial","non-muscle-invasive-bladder-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3176","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3176","title":"[ 212 Pb] Pb-MP0712 in patients with small cell lung cancer and other Delta-like ligand 3–expressing solid tumors: A phase 1/2a study to assess safety, tolerability, and efficacy.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05281471","nct06463665","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4037","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4037","title":"A phase 1 study of SHR-3821, an ADCC-enhanced CLDN18.2/4-1BB bispecific antibody, in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5014","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5014","title":"A phase 1, first-in-human (FIH) study evaluating the safety, pharmacokinetics, and efficacy of ABBV-969 in patients with metastatic castration-resistant prostate cancer (mCRPC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05281471","nct06463665","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3678","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3678","title":"A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 T-cell engager in participants with advanced or metastatic microsatellite-stable (MSS)/microsatellite instability–low (MSI-L) colorectal cancer (CRC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06922591","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4242","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4242","title":"A phase 1/2 study of BDC-4182, a Claudin 18.2–targeting next-generation immune-stimulating antibody conjugate (ISAC), in patients with advanced gastric and gastroesophageal cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bdc-4182"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["cldn18-2"],"cancers":["gastric"],"technologies":["immune-stimulating-adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps1151","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps1151","title":"A phase 1/2 study of EP0062 (vosilasarm), a first-in-class oral selective androgen receptor modulator (SARM), in combination with standard-of-care endocrine therapy +/- targeted therapies in patients with advanced or metastatic AR+/ER+/HER2− breast cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ep0062"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["androgen-receptor","her2"],"cancers":["breast-cancer"],"technologies":["endocrine-therapy"]}},{"doi":"10.1200/jco.2026.44.16_suppl.6062","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6062","title":"A phase 1/2 study of the next-generation nectin-4–targeting antibody-drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic head and neck squamous cell carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["crb-701"],"trials":["nct05283226","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["nectin4"],"cancers":["head-and-neck"],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.1072","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1072","title":"A phase 1/2 trial of tersolisib (LY4064809/STX-478), a pan-mutant-selective PI3Kα inhibitor (PI3Kαi), in PIK3CA -mutant advanced solid tumors: Updated results from PIKALO-1.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tersolisib"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["pik3ca"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps11587","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps11587","title":"A phase 1/2, multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplastic activity of LNTH-2403, a LRRC15-targeted 177 lutetium-labeled monoclonal antibody, in patients with relapsed/refractory osteosarcoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06922591","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05947851","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["osteosarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1078","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1078","title":"BL0175, a novel nano-mediated polypeptide conjugate of protein degrader, in patients (pts) with locally advanced/metastatic HR+/HER2− breast cancer (HR+, HER2- LA/mBC): Initial results from a phase 1 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct04862663","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3102","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3102","title":"EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a phase 1/2 study EIK1003-001 in advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["paclitaxel"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["parp"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5532","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5532","title":"GT101 autologous TIL therapy in patients with recurrent and metastatic cervical cancer: A phase 1 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07051486","nct04906993","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["cervical"],"technologies":["til-therapy"]}},{"doi":"10.1200/jco.2026.44.16_suppl.5070","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5070","title":"Initial results of a phase 1 dose exploration and expansion study of xaluritamig plus abiraterone acetate (AA) in patients (pts) with mCRPC.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["abiraterone","xaluritamig"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8609","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8609","title":"Reduction in circulating tumor DNA (ctDNA) in relation to radiographic response and tumor PD-L1 expression in a phase 1 study of PDL1V (PF-08046054) in patients with non-small cell lung cancer (NSCLC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pf-08046054"],"trials":["nct05318573","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["pdl1"],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11518","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11518","title":"Safety and pharmacokinetics (PK) of lurbinectedin (lurbi) in pediatric patients (pts) with relapsed/refractory (R/R) solid tumors and preliminary antitumor activity in pediatric and young adult pts with R/R Ewing sarcoma (EwS): Results from a phase 1 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["lurbinectedin"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05947851","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["ewing-sarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5117","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5117","title":"Survival outcomes and subgroup efficacy analysis of Ga-68-NGUL and Lu-177-DGUL (pocuvotide satetraxetan) in patients with mCRPC: Results from a phase 1/2 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05281471","nct06463665","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2673","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2673","title":"A logic-gated chimeric antigen receptor T-cell (CAR T) therapy with an armored, membrane-tethered IL-12 booster in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH): EVEREST-2, a phase 1/2 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3172","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3172","title":"A phase 1 first-in-human study of BGM-2121 in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2523","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2523","title":"A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti–PD-1) in patients with solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tislelizumab"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15108","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15108","title":"A phase 1 study of CT-01, a dual molecular glue degrader of GSPT1 and NEK7, as monotherapy and in combination with everolimus in patients with hepatocellular carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["everolimus"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3156","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3156","title":"A phase 1 study of HWK-007, a next-generation, protein tyrosine kinase 7 (PTK7)–targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.e14606","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e14606","title":"A phase 1 study of the safety, pharmacokinetics, and pharmacodynamics of intermittent oral PRTX007, an IRF7-biased TLR7 agonist prodrug.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["prtx007"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3179","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3179","title":"A phase 1, first-in-human study of DS9051, a novel targeted protein degradation molecule, in patients with advanced/metastatic adrenocortical carcinoma (ACC) or metastatic castration-resistant prostate cancer (mCRPC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["adrenocortical","prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3088","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3088","title":"A phase 1, first-in-human study of OP-3136, a novel oral selective KAT6A/B inhibitor, as monotherapy in advanced solid tumors and in combination with endocrine therapy in ER+, HER2− advanced breast cancer (ABC): Preliminary results.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":["endocrine-therapy"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3180","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3180","title":"A phase 1, first-in-human, open-label, dose-escalation and -expansion study of gamitrinib, a first-in-class, mitochondria-directed inhibitor of the molecular chaperone heat shock protein-90 (Hsp90) in patients with advanced cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["metastatic-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2675","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2675","title":"A phase 1/2 dose-escalation/expansion study of REGN10597 (anti–PD-1–IL2Rα-IL2) in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5639","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5639","title":"A phase 1/2 study of REGN5668, a MUC16×CD28 costimulatory bispecific antibody, in combination with other targeted therapies, in patients with recurrent ovarian or endometrial cancer: Trial in progress update.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["muc16"],"cancers":["endometrial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2686","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2686","title":"A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating MDX2004 monotherapy in patients with advanced tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8095","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8095","title":"BL0020, a novel tumor microenvironment (TME)-targeting nano-mediated polypeptide-drug conjugate (NMPDC), in patients with advanced solid tumors: Updated results from the small cell lung cancer (SCLC) subset of a phase 1 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3164","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3164","title":"First-in-human clinical evaluation of ST-01156, an optimized and selective degrader of RNA-binding motif 39 (RBM39): A phase 1 study in advanced solid malignancies with a focus on RBM39-dependent cancers.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4517","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4517","title":"Initial results from EXCEED, a phase 1 study of LY4101174, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["nectin4"],"cancers":["muscle-invasive-bladder-cancer"],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.4508","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4508","title":"Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["nectin4"],"cancers":["muscle-invasive-bladder-cancer"],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2679","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2679","title":"OP-NEU-101: A phase 1/2 open-label, dose finding and expansion study to investigate the safety and effectiveness and determine the optimal dose of N17350 administered intratumorally in participants with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8525","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8525","title":"SHR-1826, a c-MET directed antibody-drug conjugate (ADC), in advanced solid tumors: Updates from a phase 1 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps9606","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps9606","title":"SILVER (supplementing tebentafusp with subcutaneous IL-2 to verifiably eradicate radiological progression): A phase 1/2 trial of IL-2 with tebentafusp upon first radiological progression on first-line tebentafusp alone.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tebentafusp"],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4015","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4015","title":"Tegavivint, a downstream Wnt/β-catenin inhibitor: Dose-finding results from a phase 1/2 trial in advanced hepatocellular carcinoma (aHCC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2681","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2681","title":"Updated design of INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5544","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5544","title":"A phase 1 dose-escalation and -expansion study of AFN0328, a novel mRNA-based immunotherapy, in patients with HPV16/18-associated high-grade squamous intraepithelial lesions.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3112","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3112","title":"HRS-5041, an androgen receptor degrader, in metastatic castration-resistant prostate cancer: A phase 1, multicenter, first-in-human study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["androgen-receptor"],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2608","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2608","title":"RAISIC-1: A phase 1/2 clinical trial of the GPR65 inhibitor PTT-4256—Preliminary safety, tolerability, pharmacokinetic, and pharmacodynamic results.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2013","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2013","title":"Updated overall survival, safety, and neurologic function outcomes from a phase 1 trial of bivalent chimeric antigen receptor (CAR) T cell therapy in recurrent glioblastoma (GBM).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221","nct04036682","nct07109726","nct07328217","nct06265727","nct05914116","nct06383052","nct06725758","nct06163430","nct07160725","nct05394831","nct07629726","nct06384807","nct07185880","nct06055439","nct05463263","nct06480240","nct05886920","nct06616766","nct05908409","nct05150691","nct05547061","nct05199272","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1123","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1123","title":"JSKN016, a first-in-class anti-TROP2/HER3 bispecific antibody-drug conjugate (ADC), in patients (pts) with HER2-negative locally advanced or metastatic breast cancer: Results from a phase I study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129","jskn016"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["trop2","her2","her3"],"cancers":["breast-cancer"],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps11599","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps11599","title":"A phase I/II study of safety/efficacy using lurbinectedin, combined with ipilimumab, and nivolumab, for advanced soft tissue sarcomas (NCT05876715).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["lurbinectedin","ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct05281471","nct06463665","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["sarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2674","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2674","title":"A phase I, open-label, dose-escalation study of CAR001 (mRNA-engineered Nb-CAR.BiTE-γδ T cells) in patients with relapsed or refractory solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03686124","nct05958121","nct03709680","nct06150885","nct05704049","nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct05947851","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4205","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4205","title":"Final results and preliminary correlative analysis of a phase I study of anetumab ravtansine in combination with checkpoint inhibitors and gemcitabine in mesothelin-positive advanced pancreatic adenocarcinoma (NCI10208).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["anetumab-ravtansine","gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","eb-mf-car-nk-01"],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["mesothelin"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5640","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5640","title":"RegeNovar: A phase I/II study of ubamatamab plus carboplatin, paclitaxel, and bevacizumab as salvage therapy in ovarian cancer with poor response to first-line chemotherapy.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","carboplatin","paclitaxel","ubamatamab"],"trials":["nct06891833","nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16410","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16410","title":"A phase I trial of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in metastatic or unresectable pancreatic ductal adenocarcinoma (PDAC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine","emavusertib"],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["pancreatic"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2618","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2618","title":"First-in-class PD-1/IL-2 α-bias bispecific antibody IBI363 (TAK-928) in patients (pts) with advanced immunotherapy-resistant non–small cell lung cancer (NSCLC): Updated results from a phase I study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129","tak-928","ibi363"],"trials":["nct05318573","nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["pd1"],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15160","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15160","title":"Safety and efficacy of BAL0891 as monotherapy and in combination with paclitaxel: Results from a phase I study in advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["paclitaxel"],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct05281471","nct06463665","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps6599","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps6599","title":"A phase I study of HPB-092, a dual FLT3/IRAK4 inhibitor, in relapsed or refractory acute myeloid leukemia.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05211570","nct05704049","nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct05947851","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["flt3"],"cancers":["leukaemia"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2663","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2663","title":"A phase I study of pomalidomide and nivolumab (Pom/Nivo) in patients with virus-associated malignancies with and without HIV.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pomalidomide","nivolumab","relatlimab-nivolumab"],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2601","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2601","title":"A phase I trial on the safety, tolerance, and preliminary efficacy of intracavitary injection of in situ vaccines (FOLactis) in patients with advanced solid tumors complicated with malignant pleural effusion.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct05281471","nct06463665","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2671","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2671","title":"A phase I/IIa dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety and preliminary efficacy of tri-specific antibody (SOA101) in subjects with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct05281471","nct06463665","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9525","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9525","title":"A phase I/IIa, first-in-human, multicenter, monotherapy and combination therapy with nivolumab dose-finding study of [ 212 Pb]VMT01 melanocortin-1-receptor–targeted, image-guided, alpha-particle therapy in subjects with previously treated unresectable or metastatic melanoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nivolumab","relatlimab-nivolumab"],"trials":["nct05732805","nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2690","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2690","title":"Cohort expansion of a phase I study of PLN-101095, a first-in-class dual α v β 8 /α v β 1 integrin inhibitor, in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab"],"trials":["nct05224141","nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":["checkpoint-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.8089","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8089","title":"DAREON-8: Updated efficacy and safety from a phase I dose-escalation/expansion trial of first-line (1L) obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab"],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct05281471","nct06463665","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16052","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16052","title":"Preliminary safety and efficacy of SYS6010 combined with enlonstobart in patients with recurrent or metastatic esophageal cancer: Results from a phase I/II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sys6010"],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct05281471","nct06463665","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8617","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8617","title":"Safety and efficacy of APS03118, a next-generation RET inhibitor, in patients with non-small cell lung cancer (NSCLC): Results from a phase I clinical trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05318573","nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct05281471","nct06463665","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3040","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3040","title":"Safety, efficacy, and pharmacokinetics of XNW28012, a tissue factor antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor (TOP1i) payload, in patients with advanced solid tumors: Results from a phase I/II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct05281471","nct06463665","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["tissue-factor"],"cancers":[],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.10001","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.10001","title":"SPARTO: A phase I study of PD-1 inhibitor spartalizumab (PDR001) in combination with low dose of pazopanib in pediatric relapsed/refractory tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["spartalizumab","pazopanib"],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct05947851","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3564","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3564","title":"NALIRIFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer: A phase I study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nalirifox"],"trials":["nct06992258","nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2606","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2606","title":"Neoadjuvant chemokine modulation of the tumor microenvironment (TME) in resectable metastatic colorectal cancer: Results from a phase I study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06992258","nct07412613","nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2046","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2046","title":"A phase I study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of KH617 for patients with advanced solid tumors (including diffuse gliomas of adulthood).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4638","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4638","title":"A phase I, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activities of GenSci139 in patients with solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06922591","nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3158","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3158","title":"A phase I, multi-center study of KIVU-107, a novel PTK7-targeting antibody-drug conjugate (ADC), in participants with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5635","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5635","title":"A phase I, open-label, dose-finding, safety, tolerability, and exploratory trial of intraperitoneal THEO-260 in patients with high-grade serous or endometrioid ovarian cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["theo-260"],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps9602","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps9602","title":"A phase I/II clinical study of DOC1021 (dubodencel) dendritic cell immunotherapy for refractory melanoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["doc1021"],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2688","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2688","title":"A phase I/IIa study to evaluate the safety and tolerability, activity, and PK of a potential novel CNTN4-targeted checkpoint inhibitor, EP0089, in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3035","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3035","title":"BC3195, a novel ADC targeting cadherin-3 (CDH3): Preliminary results of a phase I study in patients with advanced solid malignancies (study BC3195-102).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4031","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4031","title":"CLDN18.2–targeting antibody-drug conjugate BA1301 in advanced solid tumors: Results from a phase I clinical trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.8523","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8523","title":"Dose-escalation results from a phase I study of FZ-AD004, a TROP2-directed ADC, in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["trop2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2553","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2553","title":"Erythrocyte–anti–PD-1 conjugates in patients with advanced solid tumors resistant to anti–PD-1/PD-L1 therapy: Long-term follow-up of a phase I trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["pdl1","pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2059","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2059","title":"Rituximab pre-conditioning in a phase I study of CARv3-TEAM-E for recurrent glioblastoma (GBM): The INCIPIENT trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["rituximab"],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5063","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5063","title":"A phase I study of [225Ac]Ac-PSMA-XT, a novel alpha-particle–emitting radioligand therapy, in patients with metastatic castration-resistant prostate cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["psma"],"cancers":["prostate"],"technologies":["radioligand-therapy"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2667","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2667","title":"A phase I trial evaluating an optimized B7-H3xCD3 T cell engager for treatment of solid cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2603","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2603","title":"A phase I window-of-opportunity trial of intraperitoneal, intratumoral lipopolysaccharide in peritoneal metastases: Safety and immune remodeling from the RIOT-1 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15146","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15146","title":"A phase I/IIa, image-guided, alpha-particle therapy study of [ 203 Pb]Pb-PSV359 and [ 212 Pb]Pb-PSV359 in patients with solid tumors that are known to be fibroblast activation protein (FAP)–positive.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3074","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3074","title":"Diagnostic performance, safety, and biodistribution of [ 68 Ga]Ga-OncoACP3 for PET imaging in prostate cancer: A phase I clinical trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps12169","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps12169","title":"Exercise therapy in survivors of gastroesophageal cancer: A phase I, randomized dose-finding study of an individually tailored, remotely supervised exercise intervention.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":["exercise-oncology"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4270","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4270","title":"FusionVAC22_02, a phase I clinical trial in progress: Adjuvant DNAJB1-PRKACA fusion transcript–based peptide T-cell activator for fibrolamellar hepatocellular carcinoma (FLC) and other tumor entities carrying the oncogenic driver fusion.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2072","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2072","title":"Intrathecal iPSC-derived natural killer cells combined with the Stupp regimen for newly diagnosed WHO grade 4 glioma: A phase I trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2537","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2537","title":"Tumor infiltrating lymphocytes (LM103 infusion) in solid tumors: A phase I trial evaluating clinical and immunological anti-tumor activity.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07123454","nct05123482","nct05170958","nct07811037","nct07069062","nct04685226","nct07243340","nct06971523","nct07229612","nct06712680","nct05315167","nct07253116","nct06797986","nct07392736","nct05970016","nct06245330","nct06953323","nct02734004","nct06737731","nct07136142","nct05902988","nct07075328","nct06682780","nct05761223","nct06247995","nct06922357","nct06239155","nct06959615","nct07744763","nct06064812","nct05615974","nct06084884","nct04539496","nct05415072","nct06741644","nct07417189","nct07777211","nct07083323","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7509","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7509","title":"Updated results from inMMyCAR, the ongoing first-in-human phase 1 study of KLN-1010 in patients (pts) with relapsed and refractory multiple myeloma (RRMM).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e18085","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e18085","title":"Phase 1 study of induction chemoimmunotherapy (ICI) with cemiplimab in combination with cisplatin and docetaxel (TPI) in locally advanced squaous cell carcinoma of the head and neck (LA SCCHN).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cemiplimab","docetaxel","gemcitabine-cisplatin","cisplatin"],"trials":["nct04514419","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8096","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8096","title":"Updated results of the phase 1 dose escalation and expansion study of alveltamig (ZG006), a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["zg006"],"trials":["nct07365241","nct07744256","nct07480213","nct07325136","nct05431270","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["dll3"],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6028","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6028","title":"Efficacy and safety of pralsetinib in advanced or metastatic RET -altered thyroid cancer (TC): Final analysis of the phase 1/2 ARROW study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pralsetinib"],"trials":["nct05281471","nct06463665","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126","arrow-thyroid"],"targets":[],"cancers":["thyroid"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11520","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11520","title":"Efficacy of velzatinib (IDRX-42) in patients with advanced/metastatic GIST by line of therapy and circulating tumor DNA response in the phase 1/1b StrateGIST 1 trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["velzatinib","idrx-42"],"trials":["nct05281471","nct06463665","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2504","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2504","title":"RP2 oncolytic immunotherapy alone and in combination with nivolumab (nivo) in patients with advanced solid tumors: Final safety, efficacy, and biomarker results from the phase 1 first-in-human (FIH) study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nivolumab","relatlimab-nivolumab"],"trials":["nct05281471","nct06463665","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7512","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7512","title":"Belantamab mafodotin with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible, newly diagnosed multiple myeloma patients: Phase 1/2 BelaDRd study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belantamab-mafodotin","dexamethasone","lenalidomide","daratumumab"],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2564","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2564","title":"Depletion of T-regulatory cells by denileukin diftitox-cxdl (E7777) in combination with pembrolizumab in relapsed/refractory (r/r) gynecologic malignancies: Phase 1 study results.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["denileukin-diftitox","pembrolizumab"],"trials":["nct05224141","nct05947851","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3032","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3032","title":"First-in-human phase 1 study of TQB6411, an EGFR/c-Met bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129","tqb6411"],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126","nct07617805"],"targets":["egfr"],"cancers":[],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps7103","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps7103","title":"Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["glofitamab"],"trials":["nct05487170","nct07075328","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["dlbcl","non-hodgkin-lymphoma","hodgkin-lymphoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3170","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3170","title":"Phase 1/2 study of the novel Werner helicase inhibitor EIK1005 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including MSI-H or dMMR tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","eik1005"],"trials":["nct05224141","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4202","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4202","title":"Proglumide, gemcitabine (GEM), and nab-paclitaxel (NAB-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC): Results of the phase 1 PROGEM trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["pancreatic"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2607","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2607","title":"Safety and efficacy results from a first-in-human, phase 1/2 study of ASKG915, an anti-PD-1/pro-IL-15 bifunctional fusion protein, for patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06277219","nct05281471","nct06463665","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5038","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5038","title":"Safety and preliminary efficacy of M9466 (HRS-1167) in combination with abiraterone acetate and prednisone/prednisolone (AA-P) in patients (pts) with metastatic prostate cancer in the phase 1 DDRiver 501 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["abiraterone","prednisone"],"trials":["nct05281471","nct06463665","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15154","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15154","title":"Debio 0123 (zedoresertib), a selective WEE1 inhibitor, in combination with carboplatin in adult patients with platinum-resistant ovarian cancer: Expansion part of the Debio0123-101 phase 1 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["carboplatin","platinum-etoposide"],"trials":["nct06891833","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["wee1"],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7502","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7502","title":"First results from the phase 1/2 LINKER-AL2 trial of linvoseltamab (LINVO) in patients (pts) with relapsed or refractory (RR) systemic light chain (AL) amyloidosis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["linvoseltamab"],"trials":["nct05704049","nct05947851","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2629","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2629","title":"Phase 1 dose escalation of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies post checkpoint inhibition.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129"],"trials":["nct05431270","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["pdl1","pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2544","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2544","title":"Phase 1 dose escalation study of CD34 selected CD19 directed CAR T with metabolic programming in relapsed/refractory B-cell lymphoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05431270","nct05947851","nct07075328","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["cd19"],"cancers":["non-hodgkin-lymphoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2518","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2518","title":"Phase 1 study of NTX1088, a first-in-class anti-PVR monoclonal antibody, as monotherapy and combined with pembrolizumab, in patients with advanced solid malignancies.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab"],"trials":["nct05224141","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6547","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6547","title":"Phase 1 study of venetoclax combined with a 10-day regimen of decitabine in subjects with high-risk acute myeloid leukemia.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["decitabine-cedazuridine","venetoclax","decitabine"],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["leukaemia"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2041","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2041","title":"Phase 1, first-in-human (FIH) study evaluating safety and efficacy of ABBV-706: Results from patients with high-grade central nervous system (CNS) tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["abbv-706"],"trials":["nct05281471","nct06463665","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3163","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3163","title":"Phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of TGW101 in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05281471","nct06463665","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11510","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11510","title":"Phase 1/2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in patients with relapsed or refractory (R/R) Ewing sarcoma and chondrosarcoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["yl201"],"trials":["nct05704049","nct05947851","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["ewing-sarcoma"],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.2005","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2005","title":"Phase 1/2a study of concomitant radiotherapy with olaparib and temozolomide in unresectable high-grade glioma patients: Final results from the phase 2a step (OLA-TMZ-RTE-01).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide","olaparib"],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5131","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5131","title":"Randomized phase 1 trial of cisplatin-based chemotherapy with or without sodium thiosulfate for men with metastatic germ cell tumor (GCT).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sodium-thiosulfate","gemcitabine-cisplatin","cisplatin"],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4640","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4640","title":"RNDO-564-001: A first-in-human, phase 1/1b study of RNDO-564, a costimulatory bispecific antibody for the treatment of advanced bladder cancer and other Nectin-4–positive solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129"],"trials":["nct06277219","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["nectin4"],"cancers":["urothelial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4106","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4106","title":"Safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients with biliary tract cancer (BTC): A first-in-human phase 1/2a study (BLUESTAR).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["puxitatug-samrotecan"],"trials":["nct05281471","nct06463665","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["cholangiocarcinoma","biliary-tract-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3018","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3018","title":"The efficacy and safety of azvudine (FNC) in phase 1 investigator-initiated study in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05281471","nct06463665","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5515","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5515","title":"Updated safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients (pts) with endometrial cancer (EC) or ovarian cancer (OC): Phase 1/2a BLUESTAR study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["puxitatug-samrotecan"],"trials":["nct05281471","nct06463665","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["endometrial","ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11501","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11501","title":"Velzatinib (IDRX-42) as 1L or 2L therapy for advanced gastrointestinal stromal tumors (GISTs) by KIT mutation status: A subset analysis of the phase 1/1b StrateGIST 1 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["velzatinib","idrx-42"],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2536","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2536","title":"Clinical and translational results from the phase 1 portion of the phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05704049","nct05947851","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2521","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2521","title":"CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors: Updated results from an open-label, multicenter, phase 1 first-in-human study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ai-081"],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["ctla4","pd1","vegf"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8520","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8520","title":"DZD6008, a fourth-generation EGFR TKI, in pretreated NSCLC patients with EGFR C797X mutations: Results from phase 1/2 studies.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06922591","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126","nct07617805"],"targets":["egfr"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3078","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3078","title":"Farnesyl transferase inhibitor (FTI) darlifarnib (KO-2806) in combination with adagrasib in KRAS G12C mutated (mut) advanced solid tumors: Preliminary results from the FIT-001 phase 1 first-in-human trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["adagrasib"],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["kras"],"cancers":[],"technologies":["kras-inhibitors"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3168","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3168","title":"First-in-human phase 1 dose escalation and expansion study of PIN-5018, a CK1α-selective molecular glue degrader, in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05431270","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1069","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1069","title":"HRS-8080, an oral selective estrogen receptor degrader (SERD), in ER+/HER2− advanced breast cancer (aBC) with ESR1 mutations ( ESR1 m): Results from a first-in-human phase 1 trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["hrs-8080"],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["estrogen-receptor","her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9526","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9526","title":"Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in patients with CPI-refractory cutaneous melanoma: Promising results from an ongoing phase 1/2 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nivolumab","relatlimab-nivolumab"],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5513","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5513","title":"NAPISTAR 1-01: Results of phase 1 dose escalation of monotherapy with TUB-040, a novel NaPi2b-targeting exatecan ADC, in patients (pts) with platinum-resistant ovarian cancer (PROC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["platinum-etoposide"],"trials":["nct05431270","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5514","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5514","title":"Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting antibody-drug conjugate: Results from patients with platinum-resistant ovarian/primary peritoneal/fallopian tube cancer (PROC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["telisotuzumab-adizutecan","platinum-etoposide"],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["ovarian"],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2687","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2687","title":"Phase 1 clinical trial investigating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AB821 in adult patients with locally advanced or metastatic melanoma and other solid tumor malignancies (NCT 07027488).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05732805","nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9527","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9527","title":"Phase 1 evaluation of the PRAME-targeted ImmTAC brenetafusp in advanced melanoma (Mel).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["brenetafusp"],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["prame"],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps6134","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps6134","title":"Phase 1 study of VLPONC-01, a novel IL-12–encoding saRNA viral replicon particle, alone and in combination with pembrolizumab in head and neck cancer patients: Protocol summary.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab"],"trials":["nct05224141","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps6601","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps6601","title":"Phase 1, open-label, multi-center trial of RPT1G in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes/neoplasms.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05211570","nct05947851","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["mds","cmml","leukaemia"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4208","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4208","title":"Phase 1/2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in patients with previously treated advanced pancreatic ductal adenocarcinoma (PDAC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["yl201"],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["pancreatic"],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.3141","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3141","title":"Phase 1/2 trial of ATR inhibitor berzosertib plus immune checkpoint inhibitor avelumab in patients with advanced cancers with DNA damage response (DDR) gene alterations: Tumor microenvironment–mediated pathways of resistance from correlative data.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["avelumab"],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8012","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8012","title":"Preliminary results from an ongoing phase 1 study of LB2102, a dnTGFBR2-armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory SCLC or LCNEC.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05704049","nct05947851","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["dll3"],"cancers":[],"technologies":["car-t"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5141","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5141","title":"ProTACT: A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [ 225 Ac]Ac-FL-020, a PSMA-targeted radioconjugate, in patients with mCRPC.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06277219","nct05431270","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["psma"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8522","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8522","title":"Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)─directed antibody-drug conjugate (ADC), plus pembrolizumab: Updated results from the phase 1 study (SGNB6A-001).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab"],"trials":["nct05224141","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps11598","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps11598","title":"The ATLAS study: A first-in-human phase 1/2 trial of [Ac-225]RTX-2358 in patients with relapsed or refractory soft tissue sarcoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05704049","nct05947851","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["sarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15018","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15018","title":"A global phase 1/2a trial of SHR-A1904, a CLDN18.2-targeting ADC, in advanced solid tumors expressing CLDN18.2.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3173","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3173","title":"A multicenter phase 1/1b study of AMG 436 as monotherapy and combination therapy in patients with advanced MSI-H/dMMR solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5010","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5010","title":"AcTION: Phase 1 study of [ 225 Ac]Ac-PSMA-617 ( 225 Ac-PSMA-617) in men with metastatic castration-resistant prostate cancer (mCRPC) with or without prior [ 177 Lu]Lu-PSMA ( 177 Lu-PSMA) radioligand therapy (RLT).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126","alphabreak"],"targets":["psma"],"cancers":["prostate"],"technologies":["radioligand-therapy"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps8681","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps8681","title":"An ongoing phase 1–2a study of EO1001, an oral brain-penetrant pan-ErbB inhibitor, in patients with advanced ErbB-driven solid tumors including CNS disease.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4639","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4639","title":"An open-label phase 1 study of DCC-2812 monotherapy in patients with advanced genitourinary cancers.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6009","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6009","title":"Clinical activity of REM-422, a MYB mRNA degrader, in recurrent/metastatic adenoid cystic carcinoma: Final results from the phase 1/2 dose-escalation cohort.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["rem-422"],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["salivary-gland"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3107","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3107","title":"Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["wee1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3081","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3081","title":"First data disclosure from the first-in-human phase 1/2 trial of SMP-3124LP, the first investigational pegylated liposome CHK1 inhibitor, in patients with selected advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e14570","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e14570","title":"First-in-human phase 1 evaluation of the world’s first tri-specific SIRPα–PD-1–TGF-β Fc fusion protein HCB301 in advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3109","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3109","title":"First-in-human phase 1/2 study of ETX-19477, an oral, potent, and selective PARG inhibitor, in patients with advanced solid tumors (ERADIC8).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3182","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3182","title":"IDE892 as monotherapy and in combination with IDE397 in patients with 5-methylthioadenosine phosphorylase-deleted ( MTAP -Del) advanced solid tumors (IDE892001): Phase 1 trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2506","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2506","title":"Initial phase 1 study results of NT-175 engineered T-cell therapy in TP53 R175H–mutated unresectable advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["tp53"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2519","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2519","title":"KEYNOTE-B59: An open-label, multicenter, phase 1/2 study of efdelikofusp alfa (GI-101A; CD80-IgG4 Fc-IL2v2) in advanced solid tumors (part E & F of GII-101-P101).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11568","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11568","title":"Longer-term safety of pimicotinib in tenosynovial giant cell tumor (TGCT): Integrated analysis of phase 1 and phase 3 MANEUVER trial data.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pimicotinib"],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["tenosynovial-giant-cell-tumour"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6027","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6027","title":"Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting antibody-drug conjugate: Results from patients with head and neck squamous cell carcinoma (HNSCC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["telisotuzumab-adizutecan"],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["head-and-neck"],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4262","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4262","title":"Phase 1 faecal microbiota transplantation in patients with advanced pancreatic carcinoma (FMTPanc Trial).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2669","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2669","title":"Phase 1 first-in-human trial of AG01, a recombinant humanized monoclonal antibody to progranulin/glycoprotein 88 (GP88) to determine the safety, tolerability, pharmacokinetics, and preliminary antitumor activity in subjects with advanced solid tumor malignancies.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3533","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3533","title":"Phase 1 study of the tetravalent death receptor 5 agonist ozekibart (INBRX-109) combined with chemotherapy in locally advanced or metastatic, unresectable colorectal adenocarcinoma (CRC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2542","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2542","title":"Phase 1 trial of a KRAS G12V/HLA-A*11:01–restricted TCR-engineered T-cell therapy in advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["kras"],"cancers":[],"technologies":["kras-inhibitors"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3171","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3171","title":"Phase 1, multi-center clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics and anti-cancer activity of PQ203, a first-in-class peptide drug conjugate targeting SORT1 in patients with advanced solid tumor malignancies (NCT07190469).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5140","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5140","title":"Phase 1/2 OMAHA-U01 substudy 01A: Oral steroidogenesis inhibitor opevesostat alone or in combination with other therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["opevesostat"],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3162","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3162","title":"Phase 1/2 study of CLIO-8221, a HER2-targeted, dual-payload exatecan and ATR inhibitor antibody-drug conjugate (ADC) in patients with advanced HER2-expressing solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["her2"],"cancers":[],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2666","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2666","title":"Phase I/II study of AZD6750, a CD8-guided interleukin-2 agent, alone and in combination with other anti-cancer agents in participants with advanced or metastatic solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06265025","nct06622486","nct04140500","nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2528","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2528","title":"Preliminary results of safety and antitumor activity from a first-in-human phase 1 study of AWT020, a bifunctional anti–PD-1/IL-2 fusion protein, in patients with advanced tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5050","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5050","title":"ProTACT: Preliminary data from a first-in-human, phase 1 study evaluating the safety, tolerability, and anti-tumor activity of [ 225 Ac]Ac-FL-020, a PSMA-targeted radioconjugate, in patients with mCRPC.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06277219","nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["psma"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4544","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4544","title":"A first-in-human phase 1 dose-escalation study of the oral HIF-2α inhibitor JMKX003948 in patients with renal cell carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["hif2a"],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11548","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11548","title":"A subset analysis of clinical activity and pharmacodynamic biomarkers in patients with sarcomas in the phase 1 dose-escalation study of STC-15, a METTL3 inhibitor.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["sarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1652","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1652","title":"Are socio-economic status indicators barriers for enrollment in phase 1 clinical trials?","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e14047","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e14047","title":"Clinical outcomes and safety of central nervous system tumor patients in phase 1 trials: A single-institution experience.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3033","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3033","title":"Clinical outcomes in phase 1 study of EBC-129, a first-in-class, anti–N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with gastroesophageal adenocarcinomas.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["ceacam5"],"cancers":[],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.6010","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6010","title":"Emiltatug ledadotin (Emi-Le), a B7-H4–directed antibody-drug conjugate (ADC), in patients with aggressive adenoid cystic carcinoma (ACC): Phase 1 interim analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["salivary-gland"],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.e13720","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e13720","title":"Enrollment outcomes after screening in phase 1 oncology clinical trials: Real-world evidence from a NCI-designated cancer center.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.10517","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.10517","title":"Intralesional PD-1 blockade for oral cancer prevention: First-in-class phase 1 trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["pd1"],"cancers":["oral-cavity-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e24005","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e24005","title":"Leveraging E7386 phase 1 trials for cardiac safety: Gaining concentration-QTc insights to inform early-stage oncology development.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2552","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2552","title":"Phase 1 study of META 10-19, an IL-10-expressing, anti-CD19 CAR T cell product in patients with high-risk DLBCL.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["cd19"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11516","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11516","title":"Phase 1 study results with PRAME-directed T-cell receptor (TCR) T-cell therapies in synovial sarcoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":["prame"],"cancers":["synovial-sarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3603","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3603","title":"Phase 1, FIH study of cabotamig, a TCE CDH17 X CD3, in CDH17-expressing GI malignancies.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5047","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5047","title":"Phase 1, multicenter, open-label study of HSK46575 in patients with metastatic castration-resistant prostate cancer progressing after next-generation hormonal agents and chemotherapy.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2672","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2672","title":"Phase 1, open-label clinical trial to treat stage IV cancer patients harboring multiple patient-specific mutated cell surface proteins with chimeric antibodies.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":["metastatic-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2560","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2560","title":"Preliminary phase 1 results of a MICA/B-targeted CAR T cell designed to overcome solid tumor escape mechanisms and avoid the requirement for conditioning chemotherapy.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2593","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2593","title":"Quality of life in cancer patients treated with anchored interleukin-12 (IL-12) immunotherapy: Results from a first-in-human phase 1 trial of tolododekin alfa (ANK-101).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05256290","nct03785249","nct03907852","nct04868877","nct05074810","nct05288205","nct07612280","nct06795412","nct05435248","nct07589530","nct05326243","nct06249048","nct07151040","nct07415863","nct07148128","nct06139575","nct05204862","nct04115306","nct07605962","nct07751042","nct05367778","nct07145255","nct06993844","nct04150497","nct04643418","nct06243354","nct06639256","nct06840119","nct07529808","nct05573126"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2665","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2665","title":"ASP2998, a trophoblast cell-surface antigen 2 (TROP2)–targeted immunostimulatory antibody-drug conjugate with dual payloads, in patients with locally advanced unresectable or metastatic solid tumors: A phase 1b/2 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06265025","nct06622486","nct04140500","nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct06938867","nct06590246"],"targets":["trop2"],"cancers":[],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2696","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2696","title":"Phase I study of zeaxanthin alone or in combination with pembrolizumab in metastatic solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab"],"trials":["nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct05224141","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4016","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4016","title":"A phase Ib/II trial of first-line trastuzumab, nivolumab, gemcitabine, and cisplatin in HER2-positive biliary tract cancer (HERBOT): A multi-institutional study from the Korean Cancer Study Group.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","trastuzumab","gemcitabine","cisplatin","nivolumab","relatlimab-nivolumab"],"trials":["nct06891833","nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130"],"targets":["her2"],"cancers":["cholangiocarcinoma","biliary-tract-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1044","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1044","title":"Zongertinib combination therapy in HER2-positive metastatic breast cancer (mBC): First results from a phase Ib/II trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["zongertinib"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16065","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16065","title":"A phase Ib/II clinical study of adebrelimab in combination with capecitabine and oxaliplatin for previously untreated patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["capecitabine-temozolomide","capecitabine","oxaliplatin","adebrelimab"],"trials":["nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct07239596","nct05024214","nct07590934","nct03260023","nct06590246","nct07235176","nct05720130"],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3113","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3113","title":"Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS G12C mutant solid tumors from a phase Ib/II study: 2-year follow-up from single-arm of non-small-cell lung cancer (NSCLC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["garsorasib","in10018"],"trials":["nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct05281471","nct06463665","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130"],"targets":["kras"],"cancers":["nsclc","sclc","lung-cancer"],"technologies":["kras-inhibitors"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps7582","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps7582","title":"A phase 1b/2 study of mirdametinib in combination with sirolimus for patients with RAS-mutated relapsed/refractory multiple myeloma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mirdametinib"],"trials":["nct06232096","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct05947851","nct06938867"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8648","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8648","title":"A phase Ib study of osimertinib and tegavivint as first-line therapy in patients with metastatic EGFR -mutated non–small cell lung cancer (NSCLC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["osimertinib"],"trials":["nct05318573","nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130","nct07617805"],"targets":["egfr"],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps11594","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps11594","title":"A phase Ib/II study of mirdametinib in combination with palbociclib in patients with advanced dedifferentiated liposarcoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mirdametinib","palbociclib"],"trials":["nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct07239596","nct05024214","nct07590934","nct03260023","nct06590246","nct07235176","nct05720130"],"targets":[],"cancers":["liposarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3674","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3674","title":"A phase Ib/III randomized double-blinded placebo-controlled study of suvemcitug combined with trifluridine/tipiracil for refractory metastatic colorectal cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trifluridine-tipiracil"],"trials":["nct06992258","nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130","nct07221474"],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9516","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9516","title":"Cadonilimab or ivonescimab plus axitinib in metastatic mucosal melanoma: Results from a phase Ib trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cadonilimab","ivonescimab","axitinib"],"trials":["nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130"],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1138","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1138","title":"Clinical and translational analysis of a phase Ib/II combination of atezolizumab, cobimetinib, and eribulin (ACE) to demonstrate inflammatory and metabolic programs define divergent response states.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab","cobimetinib","eribulin"],"trials":["nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3591","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3591","title":"Safety and efficacy of ifebemtinib combined with garsorasib in KRAS G12C mutant colorectal cancer from a randomized part of a phase Ib/II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["garsorasib"],"trials":["nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct05281471","nct06463665","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130"],"targets":["kras"],"cancers":["colorectal"],"technologies":["kras-inhibitors"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4251","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4251","title":"A phase 2, open-label, single-arm study of lirafugratinib in patients with previously treated, unresectable, locally advanced, or metastatic solid tumors (excluding cholangiocarcinoma) with FGFR2 fusion or rearrangement.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["lirafugratinib"],"trials":["nct06265025","nct06622486","nct04140500","nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct06590246","nct07106762"],"targets":["fgfr2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16034","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16034","title":"A phase Ib/IIa study of BAT8010+BAT1006, an anti-HER2 monoclonal antibody-exatecan conjugate combined with an ADCC-enhanced HER2 mAb in patients with advanced solid tumors: Results from the HER2-positive GC/GEJC cohort.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct07239596","nct05024214","nct07590934","nct03260023","nct06590246","nct07235176","nct05720130","nct04342910"],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4044","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4044","title":"SYS6010 combined with SYH2051 in advanced solid tumors: Results from a phase Ib/II trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sys6010"],"trials":["nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct07239596","nct05024214","nct07590934","nct03260023","nct06590246","nct07235176","nct05720130"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3106","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3106","title":"Zongertinib combined with T-DXd in HER2-positive metastatic gastric, gastroesophageal junction, or esophageal carcinoma (mGEAC): First results from a phase Ib/II dose-escalation trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["zongertinib","trastuzumab-deruxtecan"],"trials":["nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130"],"targets":["her2"],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3544","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3544","title":"A phase Ib, open-label, clinical trial of JAB21822 combined with second-line chemotherapy for metastatic colorectal cancer with KRAS G12C mutation.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06992258","nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130"],"targets":["kras"],"cancers":["colorectal"],"technologies":["kras-inhibitors"]}},{"doi":"10.1200/jco.2026.44.16_suppl.1046","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1046","title":"A phase Ib/IIa study of BAT8010+BAT1006, an anti-HER2 monoclonal antibody-exatecan conjugate combined with an ADCC-enhanced HER2 mAb in patients with advanced solid tumors: Results from the 1L HER2-positive breast cancer cohort.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct07239596","nct05024214","nct07590934","nct03260023","nct06590246","nct07235176","nct05720130"],"targets":["her2"],"cancers":["breast-her2-positive","breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3569","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3569","title":"SHR-A1811 plus chemotherapy and BP102 as 1L therapy for HER2-expressing mCRC: Data from a phase Ib/II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-rezetecan"],"trials":["nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130"],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1056","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1056","title":"TBCRC 050: A phase 1b/2 trial of niraparib and trastuzumab in HER2-positive metastatic breast cancer (MBC): Efficacy and correlative analyses.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab","niraparib"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct06891833","nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct05281471","nct06463665","nct06162572","nct05532696","nct06938867"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3167","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3167","title":"A first-in-human study of ATX-295, an oral inhibitor of KIF18A, in patients with advanced or metastatic solid tumors, including ovarian cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06265025","nct06622486","nct04140500","nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct06590246"],"targets":[],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3011","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3011","title":"An open-label, first-in-human study of SKB500 in patients with locally advanced or metastatic solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06265025","nct06622486","nct04140500","nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct06590246"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7564","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7564","title":"Updated results from the phase 2 IZALCO study: Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["dexamethasone","carfilzomib","isatuximab"],"trials":["nct06232096","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05281471","nct06463665","nct05947851","nct07106762"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7562","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7562","title":"ISABELA: A phase 2 study of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belantamab-mafodotin","dexamethasone","pomalidomide","isatuximab"],"trials":["nct06232096","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851","nct07106762"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.10039","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.10039","title":"Phase I study of the LiViT regimen (liposomal irinotecan, vincristine, and temozolomide) in pediatric patients with relapsed/refractory solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide","vincristine","irinotecan"],"trials":["nct03709680","nct06150885","nct05947851","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6034","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6034","title":"Reirradiation with NBTXR3/SBRT in combination with nivolumab or pembrolizumab for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma (HNSCC) in the phase I trial study 1100.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","nivolumab","relatlimab-nivolumab","jnj-90301900","nbtxr3"],"trials":["nct04652076","nct05224141","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":["sbrt"]}},{"doi":"10.1200/jco.2026.44.16_suppl.1041","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1041","title":"A phase II study of trastuzumab emtansine (T-DM1) combined with ribociclib in patients with HER2-positive metastatic breast cancer (RibHER).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-emtansine","trastuzumab","ribociclib"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct06891833","nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct07290088"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2632","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2632","title":"A phase II study to evaluate the safety and efficacy of BB-1701 in combination with sintilimab in patients with HER2 expression or mutation in locally advanced/metastatic breast cancer or NSCLC.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sintilimab"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct05281471","nct06463665","nct06590246","nct07290088"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e22668","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e22668","title":"A retrospective analysis of outcomes in metastatic solid tumors harboring alterations in the PI3K pathway as stratified by the presence or absence of diseases of insulin resistance.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct07109726"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e21557","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e21557","title":"Activity of NP-G2-044 (fascin inhibitor) + anti–PD-1 in ICI-resistant advanced/metastatic solid tumors with expansion in cutaneous squamous cell carcinoma (CSCC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct06590246"],"targets":["pd1"],"cancers":["cutaneous-scc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7568","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7568","title":"Comparative efficacy of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs standard of care in patients with relapsed/refractory multiple myeloma (RRMM).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belantamab-mafodotin","dexamethasone","bortezomib"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05281471","nct06463665","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11038","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11038","title":"Cost-effectiveness analysis of teclistamab plus daratumumab in relapsed or refractory multiple myeloma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["daratumumab","teclistamab"],"trials":["nct03915184","nct06232096","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05704049","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7517","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7517","title":"Final analysis of daratumumab, carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["dexamethasone","pomalidomide","carfilzomib","daratumumab"],"trials":["nct06232096","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3009","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3009","title":"Integrin α v β 3 -targeted radionuclide therapy with 177 Lu-AB-3PRGD 2 in multiple advanced metastatic solid tumors: A prospective, single-arm, single-center, investigator-initiated clinical trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct06590246"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7507","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7507","title":"MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["dexamethasone","pomalidomide","carfilzomib","teclistamab","bortezomib"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps7579","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps7579","title":"MOMENTUM: A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy of cemsidomide + dexamethasone in subjects with relapsed/refractory multiple myeloma (RRMM).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["dexamethasone"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct06194448","nct04162210","nct04126200","nct05281471","nct06463665","nct05947851","nct07106762"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7566","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7566","title":"PFS2 outcomes by prior therapy from DREAMM-8: A phase 3 study assessing belantamab mafodotin (belamaf), pomalidomide, and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belantamab-mafodotin","dexamethasone","pomalidomide","bortezomib"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","dreamm-8","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3154","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3154","title":"Safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activities of FL115, a novel IL-15 superagonist, from the first-in-human study in patients with locally advanced/metastatic solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089","nct06590246"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4030","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4030","title":"Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin, and 5-FU/levoleucovorin) as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Update from a single-arm, open-label phase I/II trial (SYLT-023).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["leucovorin","tislelizumab","oxaliplatin","paclitaxel","irinotecan"],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2591","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2591","title":"Association of SARS-CoV-2 vaccination with survival outcomes in patients with metastatic solid tumors treated with immune checkpoint inhibitors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089"],"targets":[],"cancers":[],"technologies":["checkpoint-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15115","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15115","title":"Beyond uveal melanoma: Genomic landscape and immunogenic profiles of GNAQ and GNA11 mutations in metastatic solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089"],"targets":[],"cancers":["uveal-melanoma","melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7526","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7526","title":"Comparative efficacy of linvoseltamab versus teclistamab in triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): Updated matching-adjusted indirect comparison (MAIC) with longer follow-up.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["linvoseltamab","teclistamab"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05281471","nct06463665","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7565","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7565","title":"Durable clinical benefit with B-cell maturation antigen (BCMA)–directed therapy, belantamab mafodotin plus pomalidomide and dexamethasone (BPd) in relapsed/refractory multiple myeloma (RRMM): DREAMM-8 long-term responder (LTR) analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belantamab-mafodotin","dexamethasone","pomalidomide"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","dreamm-8","nct05947851"],"targets":["bcma"],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7544","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7544","title":"Efficacy and hematopoietic recovery of high-dose melphalan with stem cell rescue as bridging to CAR-T compared with non-intensive bridging in relapsed/refractory multiple myeloma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["melphalan"],"trials":["nct06232096","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05281471","nct06463665","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e13043","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e13043","title":"Efficacy and safety of AKT inhibitor NTQ1062 combined with fulvestrant in patients with HR-positive/HER2-negative metastatic breast cancer：a proof-of-concept, multicenter, open-label, nonrandomized, phase Ib/II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fulvestrant"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct05281471","nct06463665","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130"],"targets":["her2"],"cancers":["breast-cancer","breast-hr-positive"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3090","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3090","title":"Genomic landscape of ERBB3 alterations in 5,416 metastatic solid tumors: Real-world evidence regarding biomarker-agnostic ADC strategies.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11005","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11005","title":"Impact of remote therapeutic monitoring with patient-reported outcomes on hospitalization in real-world patients receiving therapy for metastatic solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19574","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19574","title":"Matching-adjusted indirect comparison (MAIC) for belantamab mafodotin (belamaf) with pomalidomide and dexamethasone (BPd) vs daratumumab with pomalidomide and dexamethasone (DPd) in relapsed/refractory multiple myeloma (RRMM).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belantamab-mafodotin","dexamethasone","pomalidomide","daratumumab"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7510","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7510","title":"Optec/Optal: A phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["talquetamab","teclistamab","tocilizumab"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851","nct07106762"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e24138","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e24138","title":"Patient-reported quality of life and mood in prolonged responders to immune checkpoint inhibitors for metastatic solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06658353","nct06535607","nct06848699","nct05914116","nct06554795","nct05785741","nct05405595","nct06414460","nct07415863","nct06130553","nct06922357","nct06154291","nct05438329","nct05150691","nct06660654","nct06953089"],"targets":[],"cancers":[],"technologies":["checkpoint-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.11578","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11578","title":"Phase I trial of combination gemcitabine (gem) and nab-sirolimus (nab-S) in advanced leiomyosarcomas (LMS) or advanced soft-tissue sarcomas (STS) with TSC1/2 alterations: Preliminary results.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sirolimus-albumin-bound","gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["sarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19521","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19521","title":"Assessment of long-term persistence and phenotypic features of BCMA CAR-T cells in patients with relapsed or refractory multiple myeloma treated with ciltacabtagene autoleucel.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ciltacabtagene-autoleucel"],"trials":["nct03915184","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05704049","nct05947851"],"targets":["bcma"],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3177","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3177","title":"Beamion BCGC-1: Four new phase Ib/II cohorts to evaluate oral zongertinib with other agents in HER2-positive metastatic breast cancer (mBC) and metastatic colorectal cancer (mCRC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["zongertinib"],"trials":["nct06992258","nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130"],"targets":["her2"],"cancers":["colorectal","breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19502","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19502","title":"Comparison of talquetamab vs teclistamab in relapsed refractory multiple myeloma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["talquetamab","teclistamab"],"trials":["nct06232096","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1005","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1005","title":"Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab","pertuzumab","tucatinib"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct06891833","nct04514419","nct05281471","nct06463665","nct07221474"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19570","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19570","title":"Efficacy of venetoclax-based therapy in t(11;14)–positive relapsed/refractory multiple myeloma: A systematic review and meta-analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["venetoclax"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05281471","nct06463665","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7516","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7516","title":"Isatuximab plus pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: Subgroup analysis by prior anti-CD38 exposure from the phase 3 IRAKLIA trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["dexamethasone","pomalidomide","isatuximab"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":["cd38"],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8528","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8528","title":"Necitumumab plus pembrolizumab and chemotherapy for untreated advanced squamous NSCLC: Phase I/II NEJ048A/NEXUS.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","necitumumab"],"trials":["nct05224141","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2525","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2525","title":"Phase I trial of the anti-CAPRIN1 antibody TRK-950 alone or with nivolumab in Japanese patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nivolumab","relatlimab-nivolumab","trk-950"],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2626","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2626","title":"Phase I/II study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in combination with LB4330, a long-acting IL-10, in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129","lb1410","lb4330"],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["tim3","pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps9603","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps9603","title":"Phase I/IIa dose finding study of triplet regimen of relatlimab (RELA) ipilimumab (IPI), and nivolumab (NIVO) in first-line therapy of metastatic melanoma (MM) (TRINITY).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","relatlimab-nivolumab","nivolumab"],"trials":["nct05732805","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps1148","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps1148","title":"ReDiscover-2, a phase 3 study of zovegalisib (zovega, RLY-2608) + fulvestrant (fulv) versus capivasertib (capi) + fulv as treatment for locally advanced or metastatic PIK3CA -mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["capivasertib","fulvestrant","zovegalisib"],"trials":["nct07461454","nct06383767","nct06982521","nct06081959","nct05501886","nct05455619","nct04862663","nct05607004","nct04851613","nct06247995","nct06590246","nct06790693"],"targets":["pik3ca","her2","cdk4-6"],"cancers":["breast-cancer"],"technologies":["cdk46-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.1055","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1055","title":"Safety and efficacy of ZN-A-1041, a highly blood-brain barrier (BBB)–permeable HER2 tyrosine kinase inhibitor (TKI), + trastuzumab deruxtecan (T-DXd) or pertuzumab-trastuzumab (PH) in HER2-positive metastatic breast cancer (HER2+ mBC): Phase Ic expansion results from the ZN-A-1041-101-US trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","trastuzumab","pertuzumab","ro7771950"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct06891833","nct04514419","nct05281471","nct06463665"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8556","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8556","title":"A first-in-human (FIH), phase I/II open-label, dose-escalation and -expansion study of ILKN421H, an LNP mRNA encoding an IL2Rβγ selective IL-2v, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab"],"trials":["nct05224141","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2670","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2670","title":"A first-in-human phase I clinical trial evaluating the safety, tolerability, and preliminary efficacy of the novel fas ligand (FasL) inhibitor M3T01 in adults with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05281471","nct06463665","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps11586","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps11586","title":"A phase 1b study of tegavivint, a TBL1 inhibitor, with gemcitabine in patients with relapsed or refractory osteosarcoma (TIGER).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":["nct05704049","nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct05947851","nct06938867"],"targets":[],"cancers":["osteosarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4534","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4534","title":"A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic renal cell carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belzutifan"],"trials":["nct06785636","nct04924075","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct05281471","nct06463665","nct06162572","nct05532696","nct06938867","nct06590246"],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8559","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8559","title":"A phase II study of ubenimex combined with pembrolizumab, nab-paclitaxel, and carboplatin for previously untreated advanced squamous non–small cell lung cancer: TORG2241(UBE-Q).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","pembrolizumab","carboplatin"],"trials":["nct05318573","nct05224141","nct06891833","nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct06590246","nct07290088"],"targets":[],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e20171","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e20171","title":"A phase II, single-arm trial of adebrelimab plus nab-paclitaxel and carboplatin as first-line therapy for advanced thymic carcinoma: Interim efficacy and safety results.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","carboplatin","adebrelimab"],"trials":["nct06891833","nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct05281471","nct06463665","nct06590246","nct07290088"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.12080","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.12080","title":"BXQ-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN and neutropenia—A phase 1b/2a trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","oxaliplatin"],"trials":["nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct05281471","nct06463665","nct06162572","nct05532696","nct06938867"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7536","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7536","title":"Ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma responding to bridging therapy: CARTITUDE-4 cytogenetic subgroup analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ciltacabtagene-autoleucel","lenalidomide"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","cartitude-4"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2599","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2599","title":"Clinical efficacy and safety of BM201 intra-tumoral injection and radiotherapy in advanced solid tumors: Results from the phase I/IIT study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05281471","nct06463665","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7539","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7539","title":"Clinical outcomes following CAR T-cell therapy in relapsed or refractory multiple myeloma patients with baseline renal dysfunction: A TriNetX analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03915184","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05704049","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19519","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19519","title":"Comparative real-world outcomes with talquetamab and teclistamab in relapsed/refractory multiple myeloma: A TriNetX observational study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["talquetamab","teclistamab"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1050","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1050","title":"Efficacy and safety results of a prospective phase II study (IPUtrial) of inetetamab and pyrotinib in combination with utidelone for first- or second-line treatment of HER2-positive metastatic breast cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["inetetamab","pyrotinib","utidelone"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct05744687","nct05281471","nct06463665","nct07290088"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1047","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1047","title":"Efficacy, safety, and immunogenicity of pertuzumab biosimilar versus reference pertuzumab in combination with trastuzumab and docetaxel in HER2-positive metastatic breast cancer: A randomized, double-blind, multicenter, parallel group, phase III clinical trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab","pertuzumab","docetaxel"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct06891833","nct04514419","nct05281471","nct06463665"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1105","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1105","title":"Final results of a phase II study of utidelone capsule, the first solid oral microtubule stabilizer, in metastatic breast cancer patients.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["utidelone"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct07290088"],"targets":[],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps8678","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps8678","title":"First-in-human phase I, open-label, multicenter study of HJ-004, a novel EGFR-PROTAC degrader, in patients with advanced EGFR -mutated non–small cell lung cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05318573","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534","nct07617805"],"targets":["egfr"],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7534","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7534","title":"Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129"],"trials":["nct06232096","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":["bcma"],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7515","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7515","title":"Long-term outcomes with sustained minimal residual disease (MRD) negativity in belantamab mafodotin–treated patients (pts) with relapsed/refractory multiple myeloma (RRMM): An update from DREAMM-8.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belantamab-mafodotin"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","dreamm-8","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4113","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4113","title":"Neoadjuvant radiotherapy combined with lenvatinib and sintilimab in patients with resectable hepatocellular carcinoma with portal vein tumor thrombus: An open-label, single-arm, multicenter, prospective phase I clinical trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["lenvatinib","sintilimab"],"trials":["nct07412613","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4267","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4267","title":"Phase I light-dose escalation study in locally advanced pancreatic ductal adenocarcinoma: Intra-arterial (IA) padeliporfin vascular-targeted photodynamic therapy (VTP).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["padeliporfin"],"trials":["nct05431270","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["pancreatic"],"technologies":["photoimmunotherapy"]}},{"doi":"10.1200/jco.2026.44.16_suppl.8580","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8580","title":"Phase I study of IMM2510, a PD-L1/ VEGF bispecific antibody, in participants with advanced IO-treated SQ-NSCLC.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129","ai-081"],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["pdl1","vegf"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2639","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2639","title":"Phase I study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129","lb1410"],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["tim3","pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15571","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15571","title":"Phase I study of liposomal irinotecan plus fruquintinib as third- or later-line therapy for metastatic colorectal cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fruquintinib","irinotecan"],"trials":["nct06992258","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2093","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2093","title":"Phase I trial of trastuzumab deruxtecan in combination with stereotactic radiosurgery for brain metastases from HER2-positive breast cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","trastuzumab"],"trials":["nct06891833","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["her2"],"cancers":["breast-her2-positive","breast-cancer"],"technologies":["radiosurgery-srs"]}},{"doi":"10.1200/jco.2026.44.16_suppl.2621","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2621","title":"Phase I/II study of concurrent intrathecal toripalimab and pemetrexed (PM) for leptomeningeal metastases (LM) from solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["toripalimab","pemetrexed"],"trials":["nct07777822","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4036","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4036","title":"Phase I/II trial of anti-CLDN18.2/PD-L1 recombinant humanized bispecific antibody Q-1802 plus XELOX in treatment-naive CLDN18.2-positive advanced GC/GEJ.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129","capox"],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["pdl1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps7577","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps7577","title":"QUINTESSENTIAL-2: A phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["arlocabtagene-autoleucel","lenalidomide"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19516","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19516","title":"Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["teclistamab"],"trials":["nct06232096","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4193","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4193","title":"Safety and efficacy of nesuparib (JPI-547) with gemcitabine-nab-paclitaxel (GemAbraxane) or modified FOLFIRINOX (mFOLFIRINOX) in patients with locally advanced or metastatic PDAC: Results from an ongoing phase Ib/II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","folfirinox","gemcitabine-cisplatin","gemcitabine"],"trials":["nct05281471","nct06463665","nct07239596","nct05024214","nct07590934","nct03260023","nct06590246","nct07235176","nct05720130"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1042","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1042","title":"Tucatinib (TUC) combined with trastuzumab and pertuzumab (HP) as first-line (1L) maintenance therapy for HER2+ metastatic breast cancer (MBC): An in-depth safety analysis of HER2CLIMB-05.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab","pertuzumab","tucatinib"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","her2climb-05","nct06891833","nct04514419","her2climb"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5507","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5507","title":"Updated efficacy results from the phase I cervical cancer cohort of BAT8008, a TROP-2–directed antibody-drug conjugate, in patients with advanced cervical cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05281471","nct06463665","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["cervical"],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.12055","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.12055","title":"A first-in-human (FiH) phase I study of GFS202A, a GDF15/IL-6 bispecific antibody, in advanced cancer patients (pts) with pre-cachexia or cachexia.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129"],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["metastatic-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11559","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11559","title":"A phase II, multi-cohort study with pemetrexed plus cisplatin combination in patients with relapsed or refractory advanced soft tissue sarcoma: Leiomyosarcoma cohort (ALBATROSS-SARC-LMS01).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pemetrexed","gemcitabine-cisplatin","cisplatin"],"trials":["nct05704049","nct05945901","nct07777822","nct06361888","nct06844357","nct07761429","nct05744687","nct05947851","nct06590246","nct07290088"],"targets":[],"cancers":["sarcoma","leiomyosarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2509","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2509","title":"An investigator-initiated phase I study evaluating the safety, tolerability, and preliminary efficacy of a personalized neoantigen mRNA vaccine (XP-004) combined with PD-1 inhibitor as adjuvant therapy in resected pancreatic cancer patients intolerant to chemotherapy.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05281471","nct06463665","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19529","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19529","title":"Bispecific antibodies in the treatment of relapsed refractory multiple myeloma: A meta analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":["bispecific-antibody"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3160","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3160","title":"BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1 × VEGF bsAb) in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pm8002","yl202","ai-081"],"trials":["nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct06938867","nct06590246"],"targets":["pdl1","her3","vegf"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1064","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1064","title":"CAPTURE: A phase II trial evaluating alpelisib + fulvestrant vs capecitabine in advanced breast cancer patients with PIK3CA -mutant circulating DNA following CDK4/6 inhibition.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["capecitabine-temozolomide","capecitabine","fulvestrant","alpelisib"],"trials":["nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct06590246","nct07290088","nct04862663","nct06790693"],"targets":["pik3ca","cdk4-6"],"cancers":["breast-cancer"],"technologies":["cdk46-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.7541","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7541","title":"CAR-T in the older adults: Real-world survival and toxicity in patients ≥ 75 years with relapsed/refractory multiple myeloma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06232096","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps9596","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps9596","title":"Clinical trial in progress: Phase I/II study of tebentafusp in combination with liver-directed therapies for the treatment of metastatic uveal melanoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tebentafusp"],"trials":["nct06717126","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["uveal-melanoma","melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19505","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19505","title":"Comparative incidence of infections and cytopenias in BCMA- vs GPRC5D-targeting bispecific antibodies for relapsed/refractory multiple myeloma: A systematic review and meta-analysis of proportions.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":["gprc5d","bcma"],"cancers":["multiple-myeloma"],"technologies":["bispecific-antibody"]}},{"doi":"10.1200/jco.2026.44.16_suppl.3000","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3000","title":"DXC006, a first-in-class CD56-targeting antibody-drug conjugate, in advanced solid tumors: A first-in-human, phase I dose escalation clinical trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05431270","nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15035","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15035","title":"Efficacy and safety of antibody-drug conjugates in gastrointestinal malignancies: A systematic review and meta-analysis of phase I-III trials.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05281471","nct06463665","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1098","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1098","title":"Elacestrant in combination with capivasertib in patients with ER+/HER2− advanced breast cancer: Update from ELEVATE, a phase 1b/2, open-label, umbrella study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["capivasertib","elacestrant"],"trials":["nct04862663","nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct06938867","nct06590246"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2624","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2624","title":"Intrathecal (IT) PD-1/CTLA-4 antibody combined with pemetrexed (PM) for leptomeningeal metastases (LM) from solid tumors: Preliminary results of two single-center phase I studies.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pemetrexed"],"trials":["nct07777822","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["ctla4","pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e20128","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e20128","title":"Liposomal irinotecan plus cisplatin/carboplatin as second-line therapy for platinum-sensitive relapsed extensive-stage small cell lung cancer: Interim results of a phase II trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["carboplatin","irinotecan","gemcitabine-cisplatin","cisplatin","platinum-etoposide"],"trials":["nct06891833","nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct05947851","nct07290088"],"targets":[],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e12658","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e12658","title":"Neoadjuvant toripalimab combined with inetetamab, pertuzumab, and nab-paclitaxel in HER2-positive breast cancer (TORCH): A phase II trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","toripalimab","pertuzumab","inetetamab"],"trials":["nct07412613","nct05945901","nct06361888","nct06844357","nct04514419","nct07761429","nct05744687","nct07290088"],"targets":["her2"],"cancers":["breast-her2-positive","breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19504","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19504","title":"Net costs associated with inpatient (IP) administration of step-up dosing (SUD) of bispecific antibodies (bsAbs) among Medicare patients (pts) with relapsed/refractory multiple myeloma (MM).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":["bispecific-antibody"]}},{"doi":"10.1200/jco.2026.44.16_suppl.11572","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11572","title":"Phase I trial of LB-100 plus doxorubicin as first-line of advanced soft tissue sarcomas: A Spanish Sarcoma Group (GEIS) study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["doxorubicin"],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["sarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2069","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2069","title":"Phase I/II study of liposomal curcumin in combination with standard radiation and temozolomide in patients with newly diagnosed high-grade gliomas.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide"],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4169","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4169","title":"Phase I/II, first-in-human study of yttrium-90 carbon microspheres in patients with unresectable hepatocellular carcinoma: Safety and early efficacy profiles.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05281471","nct06463665","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4200","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4200","title":"Phase Ib/II clinical study of adebrelimab combined with decitabine, nab-paclitaxel, and gemcitabine as first-line (IL) treatment for metastatic pancreatic cancer (mPC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine","adebrelimab","decitabine-cedazuridine","decitabine"],"trials":["nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2659","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2659","title":"Preclinical investigations and first-in-human phase I trial of KP-483 in solid tumors: Safety, antitumor activity, and preliminary efficacy.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05281471","nct06463665","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e13051","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e13051","title":"Preliminary results of a randomized phase II trial of chidamide plus fulvestrant with or without sintilimab in HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (CISFORT).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fulvestrant","sintilimab","tucidinostat"],"trials":["simrise","nct06016738","nct07085767","nct07558733","nct06957379","nct05744687","nct06590246","nct07290088","nct04862663","nct06790693"],"targets":["her2","cdk4-6"],"cancers":["breast-cancer"],"technologies":["cdk46-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.7545","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7545","title":"Racial disparities in utilization of bispecific T-cell engager therapy for relapsed/refractory multiple myeloma: A TriNetX study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19509","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19509","title":"Real-world comparison of anti-GPRC5D bispecific therapy versus anti-BCMA treatment in relapsed/refractory multiple myeloma after prior BCMA-directed therapy.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":["gprc5d","bcma"],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19507","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19507","title":"Real-world effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myeloma: Preliminary results from the prospective, non-interventional MagnetisMM-16 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["elranatamab"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7559","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7559","title":"SATMM: A systems genetic network analysis–based risk stratification tool validated across the disease trajectory of relapsed/refractory multiple myeloma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06232096","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8527","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8527","title":"SHR-A2102 in combination with adebrelimab as first-line treatment in patients with locally advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC): Results from a phase 1b/2 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["adebrelimab","shr-a2102"],"trials":["nct05318573","nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct06938867","nct06590246"],"targets":[],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19525","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19525","title":"Treatment decision-making after CAR-T and bispecific antibody therapy in relapsed/refractory multiple myeloma: Real-world perspectives from U.S. hematologist/oncologists.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mcla-129"],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3115","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3115","title":"A first-in-human phase I/II study evaluating CTS3497, an MTA-cooperative PRMT5 inhibitor, in advanced or metastatic MTAP -deficient solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["prmt5-mtap"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4142","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4142","title":"A phase 1b/2 study of AK130 (TIGIT/TGF-β bispecific fusion protein) combined with ivonescimab in advanced biliary tract cancer (BTC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ivonescimab","mcla-129"],"trials":["nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct06938867","nct06590246"],"targets":["tigit"],"cancers":["cholangiocarcinoma","biliary-tract-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps655","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps655","title":"A phase 2 clinical trial in progress of (Z)-endoxifen plus goserelin as neoadjuvant therapy in premenopausal women with ER+/HER2– breast cancer (EVANGELINE).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["goserelin"],"trials":["nct07461454","nct06383767","nct06982521","nct06081959","nct05501886","nct05455619","nct04862663","nct05607004","nct04851613","nct07412613","nct07106762"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4024","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4024","title":"An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX in patients with HER2-low gastroesophageal adenocarcinoma (EPOC2203).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","trastuzumab","nivolumab","relatlimab-nivolumab","capox"],"trials":["nct06891833","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130"],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2642","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2642","title":"Analysis of delta-like ligand 3 (DLL3) expression levels and characteristics of patients (pts) with advanced extrapulmonary neuroendocrine carcinomas (epNECs) from an ongoing phase I trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["dll3"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19500","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19500","title":"Artificial intelligence and machine learning in relapsed/refractory multiple myeloma: A systematic review.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5529","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5529","title":"Azenosertib plus paclitaxel for platinum-resistant ovarian cancer: Results from a phase 1b study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["azenosertib","paclitaxel","platinum-etoposide"],"trials":["nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct06938867"],"targets":[],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4518","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4518","title":"Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Follow-up results from a phase 1b/2 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["toripalimab"],"trials":["nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct06938867","nct06590246","nct06823427"],"targets":[],"cancers":["muscle-invasive-bladder-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1076","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1076","title":"Efficacy and safety of SPH4336 plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer with brain metastases: A multicenter, single-arm, phase II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sph4336"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct05744687","nct05281471","nct06463665","nct07290088"],"targets":["her2"],"cancers":["breast-cancer","breast-hr-positive"],"technologies":["endocrine-therapy"]}},{"doi":"10.1200/jco.2026.44.16_suppl.e13047","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e13047","title":"Efficacy and toxicity of CDK4/6 inhibitors in early and metastatic HR+/HER2– breast cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07461454","nct06383767","nct06982521","nct06081959","nct05501886","nct05455619","nct04862663","nct05607004","nct04851613","nct05281471","nct06463665","nct06790693"],"targets":["her2","cdk4-6"],"cancers":["breast-cancer"],"technologies":["cdk46-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps6131","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps6131","title":"ERBIOTAX (TTCC-2022-02): A phase II, multicenter, randomized study of cetuximab with or without weekly paclitaxel after progression on first-line pembrolizumab plus platinum/5-FU in recurrent or metastatic head and neck squamous cell carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","paclitaxel","cetuximab","platinum-etoposide"],"trials":["nct05283226","nct05224141","nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct07290088"],"targets":[],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7508","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7508","title":"Etentamig in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)–targeted therapy.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":["bcma"],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1085","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1085","title":"Ethnicity-based comparative analysis of treatment endpoints of 30,000 HR+/HER2− metastatic breast cancer patients on CDK4/6 inhibitors (palbociclib/ribociclib/abemaciclib).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["palbociclib","abemaciclib","ribociclib"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct04862663","nct06790693"],"targets":["her2","cdk4-6"],"cancers":["breast-cancer"],"technologies":["cdk46-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.6508","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6508","title":"First-in-human dual-epitope nanobody anti-CD5 CAR-T for relapsed/refractory T-ALL/PTCL: Phase I dose-escalation and expansion results from the CONQUER trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05947851","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["peripheral-t-cell-lymphoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15097","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15097","title":"First-in-human phase I study of HSK41959, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP -deleted advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["prmt5-mtap"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3114","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3114","title":"First-in-human phase I/II study of a highly selective FGFR2 inhibitor 3HP-2827 in patients with advanced solid tumors harboring FGFR2 alterations.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["fgfr2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3028","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3028","title":"First-in-human phase I/II study of MRG006A, a first-in-class Glypican-3 (GPC3)–targeted antibody-drug conjugate (ADC), in patients (pts) with advanced hepatocellular carcinoma (HCC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["gpc3"],"cancers":["hcc"],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.7530","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7530","title":"Gaps in access to chimeric antigen receptor T-cell (CAR-T) therapy post leukapheresis: Waiting time and post-leukapheresis treatment patterns in relapsed/refractory multiple myeloma (RRMM)—Real-world evidence from U.S. claims.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2540","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2540","title":"GK01 stemness-enriched tumor-reactive T-cell therapy plus IL-2 in advanced solid tumors: ORR and clonal persistence results in a first-in-human phase I study (GUARDIAN-01).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1053","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1053","title":"Intracranial efficacy and safety of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer with central nervous system involvement: A systematic review and proportional meta-analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","trastuzumab"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct06891833","nct05281471","nct06463665"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4197","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4197","title":"LAP-NET1: Results of a phase 1b evaluating NP137, an inhibitor of the epithelial-to-mesenchymal transition, in combination with mFOLFIRINOX for the first-line treatment of locally advanced pancreatic ductal adenocarcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["folfirinox","np137"],"trials":["nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct06938867","nct06590246"],"targets":[],"cancers":["pancreatic"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7007","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7007","title":"Mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL): Updated efficacy and safety from the phase 3 SUNMO study including in second-line (2L) versus third-line plus (3L+) patient subgroups.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["polatuzumab-vedotin","mosunetuzumab","gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","oxaliplatin","rituximab"],"trials":["nct05281471","nct06463665","nct05947851","nct07075328","sunmo"],"targets":[],"cancers":["non-hodgkin-lymphoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e18063","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e18063","title":"Neoadjuvant serplulimab combined with cisplatin plus 5-fluorouracil in locally advanced head and neck squamous cell carcinoma: A phase II single-arm trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fluorouracil","serplulimab","gemcitabine-cisplatin","cisplatin"],"trials":["nct07412613","nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct06590246","nct07290088"],"targets":[],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3620","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3620","title":"Neoadjuvant treatment of QL1706 in patients with resectable microsatellite instability-high/mismatch repair-deficient colon cancer: Results from a phase 1b trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ql1706","iparomlimab-tuvonralimab"],"trials":["nct07412613","nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct06938867"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19578","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19578","title":"Ocular toxicity of belantamab mafodotin-based combination regimens in multiple myeloma: A systematic review of phase I-III clinical trials.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belantamab-mafodotin"],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2684","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2684","title":"Pharmacokinetics and pharmacodynamics evaluation in phase I trial of APX-343A, selective NOX inhibitor targeting CAF-mediated immunosuppression in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4224","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4224","title":"Phase I clinical trial evaluating dual-targeting CAR-T cells (KD-496) against CLDN18.2 and NKG2DL in advanced gastrointestinal cancers and pancreatic cancers.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15133","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15133","title":"Phase I pharmacokinetic study of high-dose vitamin C dosing regimens in patients with advanced hepatobiliary-pancreatic cancers.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3174","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3174","title":"Phase I study of [ 225 Ac]Ac-ETN029, a DLL3-targeted radioligand therapy, in patients with advanced DLL3-expressing solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["dll3"],"cancers":[],"technologies":["radioligand-therapy"]}},{"doi":"10.1200/jco.2026.44.16_suppl.3030","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3030","title":"Phase I study of BL-M05D1, a novel Claudin18.2-directed antibody-drug conjugate (ADC), in patients with locally advanced or metastatic Claudin18.2–expressing solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.3001","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3001","title":"Phase I study of BL-M14D1, a novel DLL3-directed antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small-cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), and other solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["dll3"],"cancers":["sclc","lung-cancer"],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.3514","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3514","title":"Phase I study of intraperitoneal fast-manufactured IL-9-secreting CEACAM5-targeted CAR-T cells in advanced colorectal cancer with peritoneal metastases.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["ceacam5"],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5580","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5580","title":"Phase I, multicenter, first-in-human (FIH) global study of SIM0505, an anti-CDH6 (CDH6) antibody-drug conjugate (ADC) in patients with advanced solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["cdh6"],"cancers":[],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5146","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5146","title":"Phase I/II study to evaluate AZD9750, a novel androgen receptor proteolysis-targeting chimera, alone and in combination with other anticancer agents in patients with metastatic prostate cancer (ANDROMEDA).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["azd9750"],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["androgen-receptor"],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3007","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3007","title":"Phase I/IIa study of DN022150, a novel selective noncovalent small molecule KRAS G12D inhibitor in patients with advanced KRAS G12D–mutant solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":["kras"],"cancers":[],"technologies":["kras-inhibitors"]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15167","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15167","title":"PMH-001: A first-in-human phase I study of the novel microtubule disruptor CCI-001 in patients with advanced cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["metastatic-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2076","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2076","title":"Pooled analysis of phase I and expanded access study cohorts of DOC1021 (dubodencel) in combination with chemoradiation for glioblastoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["doc1021"],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps7100","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps7100","title":"ROCKET-CLL: A randomized, open-label, multicenter, phase 3 study of rocbrutinib (LP-168) versus pirtobrutinib in covalent BTK inhibitor (cBTKi) in pretreated relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pirtobrutinib","rocbrutinib"],"trials":["apex-03","nct06943872","nct02966756","nct06588478","nct05023980","nct05254743","nct04965493","nct05704049","nct05947851","nct07075328"],"targets":[],"cancers":["non-hodgkin-lymphoma","leukaemia"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2526","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2526","title":"Safety, pharmacokinetics, and immunogenicity of HLX6018, a monoclonal antibody targeting the GARP/TGF-β1 complex, in healthy subjects: A randomized, double-blind, placebo-controlled, phase I clinical study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03960840","nct05797168","nct07221474","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7046","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7046","title":"Subsequent therapies and time to second progression-free survival events (PFS2) in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL) previously treated with zanubrutinib (zanu) or bendamustine-rituximab (BR) in SEQUOIA.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["zanubrutinib","bendamustine","rituximab"],"trials":["apex-03","nct06943872","nct02966756","nct06588478","nct05023980","nct05254743","nct04965493","nct07075328","sequoia"],"targets":[],"cancers":["non-hodgkin-lymphoma","leukaemia"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2695","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2695","title":"SYNERGY: A phase 1b/2 study of nenocorilant, a selective glucocorticoid receptor antagonist, plus nivolumab in patients with advanced solid malignancies.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nivolumab","relatlimab-nivolumab"],"trials":["nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct06938867","nct06590246"],"targets":["glucocorticoid-receptor"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2661","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2661","title":"Systemic third generation allosteric STING agonist CRD3874-SI, a novel immunotherapy, in patients with advanced solid tumors: Results from a single-agent phase I study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":["sting-agonist"]}},{"doi":"10.1200/jco.2026.44.16_suppl.11507","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11507","title":"Trabectedin with concomitant radiotherapy in resectable retroperitoneal L-sarcoma: A multicenter, prospective, phase I/II trial—A collaborative study by the Spanish (GEIS), Italian (ISG), and French (FSG) groups.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trabectedin"],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1541","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1541","title":"Validation of prognostic scores in Hispanic patients with advanced solid tumors enrolled in a single-center phase I clinical trial program.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct06590246","nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps9612","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps9612","title":"A multicenter, randomized phase Ib trial to evaluate neoadjuvant immunotherapy combination of nivolumab alone or plus ipilimumab with the IL-2 superkine MDNA11 alone or with tocilizumab in patients with high-risk, surgically resectable melanoma: The NEO-CYT trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tocilizumab","ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":["nct07412613","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130"],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15640","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15640","title":"A novel regimen of liposomal irinotecan plus capecitabine as total neoadjuvant therapy for locally advanced rectal cancer (LipCap): A phase II trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["capecitabine-temozolomide","capecitabine","irinotecan"],"trials":["nct07412613","nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct06590246","nct07290088"],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps10057","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps10057","title":"A phase 1b study of xaluritamig (a STEAP1 x CD3 T-cell engager) in pediatric, adolescent, and adult patients with relapsed/refractory (R/R) Ewing sarcoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["xaluritamig"],"trials":["nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct05947851","nct06938867"],"targets":["steap1"],"cancers":["ewing-sarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2678","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2678","title":"A phase 1b, two-arm study of tolododekin alfa (ANK-101) in combination with an anti–PD-1/PD-L1 antibody in participants with advanced non–small cell lung cancer (NSCLC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct05318573","nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct06938867","nct06590246"],"targets":["pdl1","pd1"],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3677","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3677","title":"A phase II exploratory study of iparomlimab and tuvonralimab (QL1706) combined with bevacizumab in patients with locally advanced or metastatic MSI-H/dMMR colorectal cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["iparomlimab-tuvonralimab","bevacizumab-glioma","bevacizumab","ql1706"],"trials":["nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct06590246","nct07290088"],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.10544","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.10544","title":"A phase II open-label, single-arm study to evaluate the efficacy of pembrolizumab for leukoplakia.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab"],"trials":["nct06194448","nct05224141","nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct05281471","nct06463665","nct07290088"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4629","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4629","title":"A phase II trial of neoadjuvant zanzalintinib (ZANZA) plus nivolumab (NIVO) in patients with locally advanced and/or surgically challenging clear cell renal cell carcinoma (EXPLORE-RCC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["zanzalintinib","nivolumab","relatlimab-nivolumab"],"trials":["nct07412613","nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct06590246","nct07290088"],"targets":[],"cancers":["clear-cell-rcc","rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16177","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16177","title":"A phase II, exploratory trial of cadonilimab (AK104) plus gemcitabine-cisplatin (GC) as a conversion therapy for patients (pts) with unresectable or systemic treatment–failed biliary tract cancer (BTC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","cadonilimab","gemcitabine","cisplatin"],"trials":["nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct07290088"],"targets":[],"cancers":["cholangiocarcinoma","biliary-tract-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e23006","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e23006","title":"Adoption of Bayesian Optimal Interval (BOIN) design in phase I oncology trials, trends, and challenges.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11039","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11039","title":"Association of baseline clinical factors and treatment-related variables with survival in phase I solid tumor trials.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3681","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3681","title":"Bevacizumab plus encorafenib-cetuximab in BRAF V600E mutated metastatic colorectal cancer (mCRC): A phase II study with a safety lead-in cohort (the BRAVE trial).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","encorafenib","cetuximab"],"trials":["nct06992258","nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct07290088"],"targets":["braf"],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e24150","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e24150","title":"Body mass index and the risk of hematologic adverse events in HR+/HER2- breast cancer patients treated with CDK4/6 inhibitors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07235176","nct07461454","nct06383767","nct06982521","nct06081959","nct05501886","nct05455619","nct04862663","nct05607004","nct04851613","nct06790693"],"targets":["her2","cdk4-6"],"cancers":["breast-cancer"],"technologies":["cdk46-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.11513","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11513","title":"Camrelizumab combined with liposomal doxorubicin and dacarbazine as first-line therapy for advanced, recurrent, and metastatic undifferentiated pleomorphic sarcoma: A phase II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["camrelizumab-rivoceranib","camrelizumab","doxorubicin","dacarbazine"],"trials":["nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct06590246","nct07290088"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e17544","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e17544","title":"Clinical outcomes of ethnically and racially diverse patients with gynecologic malignancies in phase I clinical trials at a single institution (2021–2024).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4535","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4535","title":"Combining HC-7366 with belzutifan in patients with renal cell carcinoma to alter tumor and microenvironment: Pharmacokinetic and pharmacodynamic (PK/PD) analysis of a phase 1b study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belzutifan"],"trials":["nct06785636","nct04924075","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct06938867"],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3075","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3075","title":"Diagnostic performance, safety, and biodistribution of [ 68 Ga]Ga-OncoCAIX for PET/CT imaging: A first-in-human phase I clinical trial in clear cell renal cell carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["clear-cell-rcc","rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11523","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11523","title":"Efficacy and safety of continuous intra-arterial cisplatin and recombinant human endostatin combined with systemic chemotherapy in osteosarcoma: A phase II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["recombinant-human-endostatin","gemcitabine-cisplatin","cisplatin"],"trials":["nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct05281471","nct06463665","nct07290088"],"targets":[],"cancers":["osteosarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4070","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4070","title":"Efficacy of durvalumab and safety by treatment period in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fluorouracil","oxaliplatin","durvalumab","leucovorin","docetaxel","flot"],"trials":["nct03164616","matterhorn","nct04514419","nct05281471","nct06463665"],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3096","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3096","title":"ETCTN 10302: A randomized phase II trial of radium-223 dichloride in combination with paclitaxel in patients with bone metastatic breast cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["radium-223","paclitaxel"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct05744687","nct07290088"],"targets":[],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8058","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8058","title":"Firmonertinib combined with cisplatin/carboplatin plus pemetrexed as neoadjuvant therapy in resectable stage II-IIIb EGFR -mutated non–small cell lung cancer: A single-arm, single-center, open-label phase II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["carboplatin","pemetrexed","gemcitabine-cisplatin","cisplatin"],"trials":["nct05318573","nct07412613","nct06891833","nct07777822","nct05744687","nct07290088","nct07617805"],"targets":["egfr"],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e23559","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e23559","title":"First-in-human phase I study of CEB-01, a biodegradable SN-38–releasing membrane, to prevent local recurrence after resection of retroperitoneal sarcoma: Updated results.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e21567","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e21567","title":"First-in-human phase I/II study of EN002-gel, a first-in-class drip inhibitor, in non-melanoma skin cancer and actinic keratosis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["skin-cancer","melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps1149","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps1149","title":"HERTHENA-Breast04: A phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus treatment of physician’s choice in hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) unresectable locally advanced or metastatic breast cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["patritumab-deruxtecan"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct05281471","nct06463665","nct06590246"],"targets":["her2","her3"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5036","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5036","title":"HRS-1167 (M9466), a PARP1 inhibitor, combined with abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: A phase 1b/2 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["abiraterone","prednisone"],"trials":["nct06785636","nct04973605","nct04538742","nct05664243","nct02586857","nct06939283","nct06162572","nct05532696","nct06938867"],"targets":["parp"],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1505","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1505","title":"Impact of remote symptom monitoring on acute care utilization in phase I cancer patients: Secondary analysis of a randomized clinical trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2077","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2077","title":"INB-200: Phase I study and characterization of gene-modified autologous gamma delta (γδ) T cells in newly diagnosed glioblastoma multiforme (GBM).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e13054","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e13054","title":"Influence of precision treatment with artificial intelligence–assisted subtyping on first-line therapeutic efficacy in HR+/HER2– breast cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct07461454","nct06383767","nct06982521","nct06081959","nct05501886","nct05455619","nct04862663","nct05607004","nct04851613","nct05281471","nct06463665"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5629","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5629","title":"Iparomlimab and tuvonralimab combined with paclitaxel and cisplatin as neoadjuvant therapy for cervical cancer: A phase II umbrella trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["iparomlimab-tuvonralimab","paclitaxel","gemcitabine-cisplatin","cisplatin"],"trials":["nct07412613","nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct07290088"],"targets":[],"cancers":["cervical"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e14010","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e14010","title":"Late line treatment in hormone receptor positive, her 2 neu positive metastatic breast cancer with fulvestrant, abemaciclib, and trastuzumab, including prolonged CNS control.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fulvestrant","abemaciclib","trastuzumab"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct06891833"],"targets":[],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8011","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8011","title":"LuSato-1: Phase I study of 177 Lu-SSO110 with 68 Ga-SSO120 companion imaging in patients with extensive stage small cell lung cancer (ES-SCLC) on maintenance treatment with immune checkpoint inhibition (ICI).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["lung-cancer"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4250","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4250","title":"Multicenter phase Ib/II study of neoadjuvant zolbetuximab plus docetaxel, oxaliplatin, and S-1 (DOS) followed by adjuvant zolbetuximab/S-1 in patients with CLDN18.2-positive resectable gastric or gastroesophageal junction adenocarcinoma (NEOCLAUD).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["zolbetuximab","oxaliplatin","docetaxel"],"trials":["nct07412613","nct04514419","nct07239596","nct05024214","nct07590934","nct03260023","nct07235176","nct05720130"],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6014","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6014","title":"Neoadjuvant ivonescimab (AK112, a PD-1/VEGF bispecific antibody) combined with nab-paclitaxel and cisplatin (AP) for resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC): An exploratory phase II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","ivonescimab","mcla-129","gemcitabine-cisplatin","cisplatin","ai-081"],"trials":["nct07412613","nct05744687","nct06590246","nct07290088"],"targets":["pd1","vegf"],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11561","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11561","title":"Neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma: Clinical outcomes and multi-omics analysis from a phase II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pegylated-liposomal-doxorubicin","doxorubicin","anlotinib"],"trials":["nct07412613","nct05945901","nct06361888","nct06844357","nct07761429","nct05744687","nct06590246","nct07290088"],"targets":[],"cancers":["sarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5049","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5049","title":"Phase I dose-escalation results of 177 Lu-NYM032 in patients with progressive metastatic castration-resistant prostate cancer (mCRPC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2070","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2070","title":"Phase I trial to evaluate the safety and tolerability of fb-PMT in patients with recurrent glioblastoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["nct03960840","nct05797168","nct07280832","nct06144671","nct06735144","nct06212076","nct06819215","nct06730009","nct05990452","nct07050641","nct07073534"],"targets":[],"cancers":["glioblastoma"],"technologies":[]}}],"errors":[]}